CapsoVision (CV) Registration Filing summary

Company overview and business model

• Commercial-stage medical technology company focused on advanced imaging and AI for GI tract diagnostics via capsule endoscopy solutions.

• Core products include CapsoCam Plus (small bowel) and CapsoCam Colon (colon), both featuring 360° panoramic imaging and cloud-based data management.

• CapsoCam Plus is FDA-cleared for small bowel use; CapsoCam Colon is in late-stage development targeting FDA clearance in 2025–2026.

• Revenue is generated from direct sales in the U.S. and through distributors internationally, with a growing focus on expanding indications and AI integration.

Financial performance and metrics

• Revenue grew from $9.8M in 2023 to $11.8M in 2024 (21% YoY increase); Q1 2025 revenue was $2.8M, up 12% YoY.

• Net losses were $11.3M in 2023, $19.9M in 2024, and $5.4M for Q1 2025; accumulated deficit reached $135.7M as of March 31, 2025.

• Gross margin declined slightly from 56% in 2023 to 54% in 2024.

• Cash balance was $4.4M as of March 31, 2025, with substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from the IPO will fund R&D for CapsoCam Plus AI, CapsoCam Colon, and clinical studies for new indications (esophageal varices, pancreatic neoplasia).

• Remaining funds will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.